Medpace Holdings Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Direxion Daily TSLA Bull 2X Shares trades at $8.04. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| MEDP | TSLL | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $620.59 | $23.03 |
52-Week Low | $393.42 | $6.74 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $8.05, down 1.95% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $8. Recent news highlights the amplified volatility inherent in this leveraged Tesla ETF, as discussed by 24/7 Wall Street on July 31, 2026.
The outlook for TSLL is heavily dependent on the performance of Tesla stock, with significant risk from daily leverage decay and market volatility. Investment opportunity exists for those betting on short-term Tesla gains, but the structure poses substantial risk of loss even if Tesla's price increases over the long term.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →